NR1H4 and metabolic dysfunction-associated steatohepatitis: Recently, in a mouse model of NASH, treatment with the FXR-TGR5 dual agonist INT-767 was able to prevent the progression of disease, with beneficial effects on liver mitochondrial function, lipid homeostasis, BA composition (i.e., decreased hydrophobicity index), liver inflammation and gut dysbiosis [25].